David E. Bautista Erazo
Co-founder & CSO
We train the immune system to resolve chronic inflammation.
For decades, medicine has managed chronic disease and treated its symptoms, with no end date.
We're building a world where chronic disease is no longer for life.
The Problem
Chronic inflammation accelerates the progression of many chronic diseases.
Inflammation is supposed to end. In chronic disease it doesn’t: the immune system stays on for years, and what evolved to repair damage starts causing it. This is an immune system that has lost the ability to regulate itself.
Today’s drugs do one of two things. They manage consequences (blood pressure, cholesterol, glucose) while the inflammation underneath keeps causing silent damage. Or they suppress the immune system, the same one that defends you.
None of them teaches the immune system to regulate itself.
-
Metabolic disease & fatty liver
Inflamed fat tissue drives insulin resistance, and in the liver, inflammation is what turns simple fat accumulation into scarring and permanent damage.
-
Cardiovascular disease
Inflammation in the artery wall is what turns a stable plaque into a dangerous one: lowering it reduces cardiovascular events even when cholesterol doesn’t change.
-
Neurodegenerative disease
The brain’s own immune cells stay activated for years, and that sustained activation accompanies and accelerates the loss of neurons.
-
Autoimmune disease
Here the immune system doesn’t just fail to switch off, it attacks the body’s own tissue, and treatment suppresses it broadly without correcting the misdirection.
The drug stays at the injection site. The protection reaches distant organs.
Instead of targeting the diseased organ, we deliver SO-001 subcutaneously. There, it trains local immune cells to adopt a regulatory profile, and that response reaches distant inflamed tissue.
-
Subcutaneous depot
SO-001 stays where it is injected and is not detected in blood. It does not need to travel through the body to work.
-
Local immune training
Immune cells gather at the injection site and SO-001 teaches them how to turn down inflammation.
-
Beyond the injection site
The response does not stay local: the trained cells travel through the body and teach other immune cells how to turn down inflammation.
-
Systemic resolution
The benefit shows up where inflammation drives disease: arteries, liver, fat and the nervous system. No broad immune suppression.
Pipeline
One platform. A growing pipeline.
SO-001
★ Lead ProgramMASH · Lead Indication
SO-002
SO-003
Let’s talk.
If you’re an investor, a partner, or a scientist who wants to understand what we’re building, we’d like to hear from you.